Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.
NCI Faces $32 Million Budget Cut In FY 2006; NIH Tells Grantees To Expect 2.35 Percent Reduction In Award Funds.
NCI Establishes New Program Project Grant Guidelines.
Chemotherapy Pioneer Howard Skipper Dead; His Work With Lekemia Cells In Mice Led To Development of Combination Therapies.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help